- Home
- DOUG vs AARD Comparison
DOUG vs AARD Comparison
Compare DOUG & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOUG
- AARD
- Stock Information
- Founded
- DOUG 1911
- AARD 2017
- Country
- DOUG United States
- AARD United States
- Employees
- DOUG N/A
- AARD N/A
- Industry
- DOUG Building operators
- AARD Biotechnology: Pharmaceutical Preparations
- Sector
- DOUG Real Estate
- AARD Health Care
- Exchange
- DOUG Nasdaq
- AARD Nasdaq
- Market Cap
- DOUG 161.5M
- AARD 186.3M
- IPO Year
- DOUG N/A
- AARD 2025
- Fundamental
- Price
- DOUG $2.84
- AARD $17.29
- Analyst Decision
- DOUG
- AARD Strong Buy
- Analyst Count
- DOUG 0
- AARD 7
- Target Price
- DOUG N/A
- AARD $31.43
- AVG Volume (30 Days)
- DOUG 544.7K
- AARD 233.4K
- Earning Date
- DOUG 11-05-2025
- AARD 11-14-2025
- Dividend Yield
- DOUG N/A
- AARD N/A
- EPS Growth
- DOUG N/A
- AARD N/A
- EPS
- DOUG N/A
- AARD N/A
- Revenue
- DOUG $1,034,406,000.00
- AARD N/A
- Revenue This Year
- DOUG $17.61
- AARD N/A
- Revenue Next Year
- DOUG N/A
- AARD N/A
- P/E Ratio
- DOUG N/A
- AARD N/A
- Revenue Growth
- DOUG 8.69
- AARD N/A
- 52 Week Low
- DOUG $1.35
- AARD $4.88
- 52 Week High
- DOUG $3.20
- AARD $19.58
- Technical
- Relative Strength Index (RSI)
- DOUG 50.90
- AARD 82.30
- Support Level
- DOUG $2.69
- AARD $10.75
- Resistance Level
- DOUG $3.01
- AARD $14.32
- Average True Range (ATR)
- DOUG 0.17
- AARD 1.15
- MACD
- DOUG -0.02
- AARD 0.65
- Stochastic Oscillator
- DOUG 31.00
- AARD 94.88
About DOUG Douglas Elliman Inc.
Douglas Elliman Inc is a real estate company. It offers sales, rentals, and new development to mortgages and title insurance, among other services related to real estate. Business is engaged in two operating segments Real Estate Brokerage and Corporate and other. The firm generates income from Commission and other brokerage revenue from existing home sales, Commission and other brokerage income from development marketing, Property management revenue and Title fees. It derives revenue from Real Estate Brokerage segment.
About AARD Aardvark Therapeutics Inc. Common Stock
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.